Drug Trial Radar · NCT07598708
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
222
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Centessa Pharmaceuticals (UK) LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
Conditions
- Narcolepsy Type 1
- Narcolepsy Type 2
Interventions
cleminorextonDrug
Oral cleminorexton capsule
PlaceboDrug
matching placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)Time frame: Baseline to week 12
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Birmingham, Alabama
Birmingham, Alabama · Recruiting
Colorado Springs, Colorado
Colorado Springs, Colorado · Recruiting
Brandon, Florida
Brandon, Florida · Recruiting
Miami, Florida
Miami, Florida · Recruiting
Miami, Florida
Miami, Florida · Recruiting
Miami, Florida
Miami, Florida · Recruiting
Miami, Florida
Miami, Florida · Recruiting
Miami Lakes, Florida
Miami Lakes, Florida · Recruiting
Orlando, Florida
Orlando, Florida · Recruiting
St. Petersburg, Florida
St. Petersburg, Florida · Recruiting
Atlanta, Georgia
Atlanta, Georgia · Recruiting
Rincon, Georgia
Rincon, Georgia · Recruiting
Stockbridge, Georgia
Stockbridge, Georgia · Recruiting
Lansing, Michigan
Lansing, Michigan · Recruiting
Flowood Mississippi
Flowood, Mississippi · Recruiting
Denver, North Carolina
Denver, North Carolina · Recruiting
Huntersville, North Carolina
Huntersville, North Carolina · Recruiting
Cincinnati, Ohio
Cincinnati, Ohio · Recruiting
Dublin, Ohio
Dublin, Ohio · Recruiting
Columbia, South Carolina
Columbia, South Carolina · Recruiting
Austin, Texas
Austin, Texas · Recruiting
Dallas, Texas
Dallas, Texas · Recruiting
Frisco, Texas
Frisco, Texas · Recruiting
Houston, Texas
Houston, Texas · Recruiting
San Antonio, Texas
San Antonio, Texas · Recruiting
Sugar Land, Texas
Sugar Land, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.